Jill Feldman: ASCO’s updated living guidelines for treating stage IV NSCLC
Jill Feldman, Co-Founder of EGFR Resisters and Lung Cancer Patient and Advocate, shared a post on LinkedIn about a paper by Lyudmila Bazhenova et al. published in Journal of Clinical Oncology:
“The American Society of Clinical Oncology (ASCO) has released updated living guidelines for treating stage IV NSCLC with driver alterations.
Yes, I posted an update 3 months ago – this ‘living’ guideline is critical given the rapidly evolving, complex treatment algorithms. However, don’t forget that patient preferences should be part of the conversation and decisions.
It is always an honor to be on this panel alongside exceptional experts who are all dedicated to providing the most up-to-date, evidence-based guidance to oncology professionals and patients.”
Authors: Lyudmila Bazhenova, Nofisat Ismaila, Fawzi Abu Rous, Angel Qin, Natasha Leighl et al.
More posts featuring Jill Feldman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023